Back to discover
Drug

Buserelin

Approved medicine
ClassGonadotropin-releasing hormone receptor agonistResearchOngoing clinical research

Also known as Buserelina, Busereline, Buserelinum.

RxNorm1825ChEMBLCHEMBL2110824ATCL02AE01UNIIPXW8U3YXDV
2
Active clinical trials
GNRHR
Primary target
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)

Clinical trial2026-06-25Results expected Q4 2033 · ClinicalTrials.gov

Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)

Clinical trial2026-06-25Results expected Q4 2026 · ClinicalTrials.gov

Age Versus Ovarian Reserve Markers Based Therapy in IN Vitro Fertilization

Clinical trial2016-07-01Terminated · ClinicalTrials.gov

A Phase III Randomized Trial Comparing Intermittent Versus Continuous Androgen Suppression for Patients With Prostate-Specific-Antigen Progression in the Clinical Absence of Distant Metastases Following Radiotherapy for Prostate Cancer

Clinical trial2013-01-10Completed · ClinicalTrials.gov

Phase III Randomized Trial Comparing Total Androgen Blockade Versus Total Androgen Blockade Plus Pelvic Irradiation in Clinical Stage T3-4, N0, M0 Adenocarcinoma of the Prostate

Clinical trial2012-01-06Completed · ClinicalTrials.gov

A Phase III Study of Neoadjuvant Docetaxel and Androgen Suppression Plus Radiation Therapy Versus Androgen Suppression Alone Plus Radiation Therapy for High-Risk Localized Adenocarcinoma of the Prostate

Clinical trial2011-01-18Terminated · ClinicalTrials.gov

The Use of Mild Stimulation Protocol in Poor Responders : a Randomized Trial

Clinical trial2010-05-01Completed · ClinicalTrials.gov

Can Fresh Embryo Transfers be Replaced by Cryopreserved-thawed Embryo Transfers in Assisted Reproductive Cycles?

Clinical trial2009-02-01Primary completion · ClinicalTrials.gov

Comparisin CC/Gonadotropin/GnRH Antagonist and Gonadotropin/GnRH Agonist in IVF Outcome.

Clinical trial2008-12-01Completed · ClinicalTrials.gov

A Phase I Study Of Combination Neoadjuvant Hormone Therapy And Weekly OGX-011 (Clusterin Antisense Oligonucleotide) Prior To Radical Prostatectomy In Patients With Localized Prostate Cancer

Clinical trial2008-09-22Completed · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Buserelin
Aliases & brands
BuserelinaBuserelineBuserelinum
RxNorm CUI
1825
ChEMBL ID
CHEMBL2110824
ATC codes
L02AE01
UNII
PXW8U3YXDV
Primary mechanism
Gonadotropin-releasing hormone receptor agonist

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

Gonadotropin-releasing hormone receptor
GNRHR · P30968
AGONISTGonadotropin-releasing hormone receptor agonist

Clinical trials

10 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
10
registered trials across all phases
LATEST COMPLETION 2013
2
Active studies
8
Late-stage (III+)
5
Completed
3
Discontinued
PHASE DISTRIBUTIONn = 10
Phase 11Phase 1 / 21Phase 35Phase 43

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Age Versus Ovarian Reserve Markers Based Therapy in IN Vitro Fertilization

TerminatedPH IVAndros Day Surgery Clinicn=1942016

The Use of Mild Stimulation Protocol in Poor Responders : a Randomized Trial

CompletedPH IVYazd Medical Universityn=1592010

Comparisin CC/Gonadotropin/GnRH Antagonist and Gonadotropin/GnRH Agonist in IVF Outcome.

CompletedPH IVYazd Research & Clinical Center for Infertilityn=2002008

Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)

Active, not recruitingPH IIIKey trialNRG Oncologyn=2,7532033

Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)

Active, not recruitingPH IIIKey trialNRG Oncologyn=2,0502026

Recent completions

Trials that read out recently, adding to the completed evidence base.

A Phase III Randomized Trial Comparing Intermittent Versus Continuous Androgen Suppression for Patients With Prostate-Specific-Antigen Progression in the Clinical Absence of Distant Metastases Following Radiotherapy for Prostate Cancer

CompletedPH IIIKey trialNCIC Clinical Trials Groupn=1,3862013

Phase III Randomized Trial Comparing Total Androgen Blockade Versus Total Androgen Blockade Plus Pelvic Irradiation in Clinical Stage T3-4, N0, M0 Adenocarcinoma of the Prostate

CompletedPH IIINCIC Clinical Trials Groupn=3612012

The Use of Mild Stimulation Protocol in Poor Responders : a Randomized Trial

CompletedPH IVYazd Medical Universityn=1592010

Comparisin CC/Gonadotropin/GnRH Antagonist and Gonadotropin/GnRH Agonist in IVF Outcome.

CompletedPH IVYazd Research & Clinical Center for Infertilityn=2002008

A Phase I Study Of Combination Neoadjuvant Hormone Therapy And Weekly OGX-011 (Clusterin Antisense Oligonucleotide) Prior To Radical Prostatectomy In Patients With Localized Prostate Cancer

CompletedPH INCIC Clinical Trials Groupn=252008
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • ClinicalTrials.gov — clinical trials